METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Lung cancer is a major cause of cancer mortality globally.
• The molecular drivers of lung cancer development and progression are not fully understood.
• Identifying novel therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the role of methyltransferase-like 7B (METTL7B) in non-small cell lung cancer (NSCLC).
• To evaluate METTL7B as a potential therapeutic target for NSCLC treatment.

Main Methods:

• Gene expression analysis comparing NSCLC and normal tissues.
• Functional studies using lentivirus-mediated shRNA to silence METTL7B.
• In vitro and in vivo assays to assess cell proliferation and tumorigenesis.
• Gene expression profiling and pathway enrichment analysis.

Main Results:

• METTL7B expression is elevated in most NSCLC tissues and correlates with advanced stages and poor survival.
• Silencing METTL7B inhibits NSCLC cell proliferation and tumorigenesis.
• METTL7B depletion leads to downregulation of cell cycle genes and G0/G1 cell cycle arrest.
• CCND1 expression is significantly reduced upon METTL7B depletion.

Conclusions:

• METTL7B plays a critical role in NSCLC cell cycle progression and tumorigenesis.
• METTL7B is essential for NSCLC development and progression.
• METTL7B represents a promising molecular target for NSCLC therapy.